Essex Bio-Technology of Guangdong will co-develop a novel biologic therapeutic discovered by Switzerland's AC Immune. The preclinical candidate is aimed at neurodegenerative diseases and neuroinflammation. In 2016, Essex invested $5 million in AC Immune for a 1% stake in the company. Essex focuses on recombinant DNA products that treat wounds, eye problems and CNS disorders. AC Immune develops treatments for neurodegenerative diseases. Financial details of the agreement were not disclosed.
